221 related articles for article (PubMed ID: 28416366)
21. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
[TBL] [Abstract][Full Text] [Related]
22. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Cheape AC; Murrell DF
Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
[TBL] [Abstract][Full Text] [Related]
23. Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
Draelos ZD; Stein Gold LF; Murrell DF; Hughes MH; Zane LT
J Drugs Dermatol; 2016 Feb; 15(2):172-6. PubMed ID: 26885784
[TBL] [Abstract][Full Text] [Related]
24. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
Ma L; Zhang L; Kobayashi M; Tao X; Qian Q; Cheng H; Liu S; Zhou Y; Chen Y; Zhang J
J Dermatol; 2023 Jul; 50(7):847-855. PubMed ID: 37154471
[TBL] [Abstract][Full Text] [Related]
26. Crisaborole: A new and effective nonsteroidal topical drug for atopic dermatitis.
Kailas A
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28834023
[No Abstract] [Full Text] [Related]
27. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin.
Kim M; Del Duca E; Cheng J; Carroll B; Facheris P; Estrada Y; Cha A; Werth J; Bissonnette R; Nocka K; Zang C; Pavel AB; Guttman-Yassky E
J Am Acad Dermatol; 2023 Aug; 89(2):283-292. PubMed ID: 37054814
[TBL] [Abstract][Full Text] [Related]
28. Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis.
Stein Gold LF; Takiya L; Zang C; Sanders P; Feldman SR
J Drugs Dermatol; 2020 Jun; 19(6):619-624. PubMed ID: 32574023
[TBL] [Abstract][Full Text] [Related]
29. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
Luger TA; Hebert AA; Zaenglein AL; Silverberg JI; Tan H; Ports WC; Zielinski MA
Paediatr Drugs; 2022 Mar; 24(2):175-183. PubMed ID: 35292919
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
Silverberg JI; Kirsner RS; Margolis DJ; Tharp M; Myers DE; Annis K; Graham D; Zang C; Vlahos BL; Sanders P
J Am Acad Dermatol; 2024 May; 90(5):945-952. PubMed ID: 38340127
[TBL] [Abstract][Full Text] [Related]
31. Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis.
Stein Gold LF; Tom WL; Shi V; Sanders P; Zang C; Vlahos B; Cha A
Dermatitis; 2024; 35(1):84-91. PubMed ID: 38206678
[No Abstract] [Full Text] [Related]
32. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
Ahmed A; Solman L; Williams HC
Br J Dermatol; 2018 Mar; 178(3):659-662. PubMed ID: 29205284
[TBL] [Abstract][Full Text] [Related]
33. Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis.
Yang H; Wang J; Zhang X; Zhang Y; Qin ZL; Wang H; Luo XY
JAMA Dermatol; 2019 May; 155(5):585-593. PubMed ID: 30916723
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
Spergel JM; Blaiss MS; Lio P; Kessel A; Cantrell WC; Takiya L; Werth JL; O'Connell MA; Zang C; Cork MJ
Allergy Asthma Proc; 2021 Sep; 42(5):425-431. PubMed ID: 34474712
[No Abstract] [Full Text] [Related]
35. Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
Simpson EL; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Ständer S; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
Acta Derm Venereol; 2019 Jul; 99(9):756-761. PubMed ID: 30896779
[TBL] [Abstract][Full Text] [Related]
36. Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers.
Zane LT; Hughes MH; Shakib S
Am J Clin Dermatol; 2016 Oct; 17(5):519-526. PubMed ID: 27335049
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2.
Thombre A; Tse S; Yeoh T; Chen R; North R; Brown M
Int J Pharm; 2020 Feb; 576():118847. PubMed ID: 31759994
[TBL] [Abstract][Full Text] [Related]
38. Allergic Contact Dermatitis to Crisaborole.
Kimyon RS; Schlarbaum JP; Liou YL; Hylwa SA; Warshaw EM
Dermatitis; 2019; 30(4):272-274. PubMed ID: 31136354
[No Abstract] [Full Text] [Related]
39. Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
Silverberg JI; Tallman AM; Ports WC; Gerber RA; Tan H; Zielinski MA
Acta Derm Venereol; 2020 Jun; 100(13):adv00170. PubMed ID: 32318744
[TBL] [Abstract][Full Text] [Related]
40. Crisaborole, Dupilumab, and Sarilumab.
Hussar DA; Lee YF
J Am Pharm Assoc (2003); 2017; 57(5):640-643. PubMed ID: 28882252
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
